

HB 829 -- ALTERNATIVE THERAPIES

SPONSOR: West

Under this bill, any person who acquires, uses, produces, possesses, transfers, or administers psilocybin for the person's own therapeutic use is not subject to state or local criminal or civil penalties if the person:

- (1) Is a Missouri veteran;
- (2) Is 21 years of age or older;
- (3) Suffers from a condition listed in the bill;
- (4) Has enrolled in a study regarding the use of psilocybin to treat such conditions;
- (5) Informs the Department of Mental Health that the person plans to acquire, use, produce, possess, transfer, or administer psilocybin under this bill;
- (6) Provides the Department of Mental Health with specified documentation and information;
- (7) Ensures the psilocybin is tested in a licensed laboratory; and
- (8) Limits the use of psilocybin to no more than 150 milligrams of psilocybin analyte during any 12 month period.

A person who assists another in any of the acts permitted under this bill and any laboratory testing of psilocybin under this bill will not be subject to state or local criminal or civil penalties.

Subject to appropriation, the Department will provide grants totaling \$3 million dollars for research on the use and efficacy of psilocybin for the treatment of conditions specified in the bill.

The Department must prepare annual reports for the Governor, Lieutenant Governor, and the General Assembly on the implementation and outcomes of psilocybin use under this bill.

No state agency will disclose to the federal government or any unauthorized third party the statewide list or any individual information of persons who meet the requirements of this bill.

This bill modifies current law on the use of investigational drugs and devices for individuals with terminal illnesses to include individuals with life-threatening or severely debilitating

conditions or illnesses. Currently, investigational drugs do not include Schedule I controlled substances. This bill repeals that prohibition.

This bill requires the Department, in collaboration with a Missouri university hospital or a contract research organization conducting FDA-approved trials, to conduct a study on the efficacy of using alternative medicine and therapies, including, but not limited to, the use of psilocybin, for the treatment of patients suffering post-traumatic stress disorder, major depressive disorder, substance use disorders, or who require end-of-life care, as provided in the bill. The study must include a study of the use of psilocybin to treat the specified conditions, as well as a literature review and the submission of various reports. No person participating in the study will be subject to criminal or civil liability or sanction for participating, except in cases of gross negligence or willful misconduct.

This bill is similar to SB 90 (2025), SCS SB 768 (2024), HCS HB 1830 (2024), HB 1154 (2023), and SB 614 (2023).